HRP20240130T1 - Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza - Google Patents
Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza Download PDFInfo
- Publication number
- HRP20240130T1 HRP20240130T1 HRP20240130TT HRP20240130T HRP20240130T1 HR P20240130 T1 HRP20240130 T1 HR P20240130T1 HR P20240130T T HRP20240130T T HR P20240130TT HR P20240130 T HRP20240130 T HR P20240130T HR P20240130 T1 HRP20240130 T1 HR P20240130T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- ethyl
- isochromen
- hydroxypyridin
- pyrazolo
- Prior art date
Links
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- 206010011224 Cough Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- JSUNXOYZTNBLOP-FQEVSTJZSA-N NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)[C@@H](C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)CN1CCN(CC1)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)[C@@H](C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)CN1CCN(CC1)C)=O JSUNXOYZTNBLOP-FQEVSTJZSA-N 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 3
- 108091007960 PI3Ks Proteins 0.000 claims 3
- 206010070488 Upper-airway cough syndrome Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 230000007247 enzymatic mechanism Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 208000013116 chronic cough Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940112141 dry powder inhaler Drugs 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- -1 (S)-3-(1-(4-amino-3-(5-hydroxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl) -4-(3-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-isochromen-1-one salicylate Chemical compound 0.000 claims 1
- XAMASEKDQZGALH-BDQAORGHSA-N 3-[(1S)-1-[4-amino-3-(5-hydroxypyridin-3-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-4-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]isochromen-1-one hydrobromide Chemical compound Br.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O XAMASEKDQZGALH-BDQAORGHSA-N 0.000 claims 1
- KTPAZYVMQXACAG-LMOVPXPDSA-N 3-[(1S)-1-[4-amino-3-(5-hydroxypyridin-3-yl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-4-[3-[(dimethylamino)methyl]phenyl]isochromen-1-one hydrobromide Chemical compound Br.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN(C)C)=O KTPAZYVMQXACAG-LMOVPXPDSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- XIXAYFLPYRBSBA-BDQAORGHSA-N C(C1=CC=CC=C1)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O Chemical compound C(C1=CC=CC=C1)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O XIXAYFLPYRBSBA-BDQAORGHSA-N 0.000 claims 1
- JEPFJVJSRWKPSM-HNUXRKMMSA-N C(\C=C/C(=O)O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN(C)C)=O Chemical compound C(\C=C/C(=O)O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN(C)C)=O JEPFJVJSRWKPSM-HNUXRKMMSA-N 0.000 claims 1
- GAICVZXNSCWQET-XREKTYCCSA-N C(\C=C/C(=O)O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O Chemical compound C(\C=C/C(=O)O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O GAICVZXNSCWQET-XREKTYCCSA-N 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- KXYVMOBQMBDISN-LMOVPXPDSA-N C1=C(C=CC2=CC=CC=C12)S(=O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN(C)C)=O Chemical compound C1=C(C=CC2=CC=CC=C12)S(=O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN(C)C)=O KXYVMOBQMBDISN-LMOVPXPDSA-N 0.000 claims 1
- VAGZDRFYDOXPRE-BDQAORGHSA-N C1=C(C=CC2=CC=CC=C12)S(=O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O Chemical compound C1=C(C=CC2=CC=CC=C12)S(=O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O VAGZDRFYDOXPRE-BDQAORGHSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- AFQLYJIJPPIGBK-LMOVPXPDSA-N Cl.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN(C)C)=O Chemical compound Cl.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN(C)C)=O AFQLYJIJPPIGBK-LMOVPXPDSA-N 0.000 claims 1
- IWDKWCZSXAHCNQ-BDQAORGHSA-N Cl.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O Chemical compound Cl.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O IWDKWCZSXAHCNQ-BDQAORGHSA-N 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- FYLXTJCKXIWKEE-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=C(C=C1)Cl)CN(C)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=C(C=C1)Cl)CN(C)C)=O FYLXTJCKXIWKEE-UHFFFAOYSA-N 0.000 claims 1
- SXZAKRCQDIJRCB-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=C(C=C1)F)CN1CCN(CC1)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=C(C=C1)F)CN1CCN(CC1)C)=O SXZAKRCQDIJRCB-UHFFFAOYSA-N 0.000 claims 1
- FFEDTYUKHMCWSK-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC(=C1)CN1CCN(CC1)C)F)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC(=C1)CN1CCN(CC1)C)F)=O FFEDTYUKHMCWSK-UHFFFAOYSA-N 0.000 claims 1
- XDCNONAJWUTNCH-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)C(C)N(C)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)C(C)N(C)C)=O XDCNONAJWUTNCH-UHFFFAOYSA-N 0.000 claims 1
- NFGBLTRSLXBEKH-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)CN(C)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)CN(C)C)=O NFGBLTRSLXBEKH-UHFFFAOYSA-N 0.000 claims 1
- JSUNXOYZTNBLOP-UHFFFAOYSA-N NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)CN1CCN(CC1)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)CN1CCN(CC1)C)=O JSUNXOYZTNBLOP-UHFFFAOYSA-N 0.000 claims 1
- XUOZVRIQNYCNLC-IXXGTQFESA-N NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)[C@@H]1N(CCC1)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)C(C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)[C@@H]1N(CCC1)C)=O XUOZVRIQNYCNLC-IXXGTQFESA-N 0.000 claims 1
- NFGBLTRSLXBEKH-KRWDZBQOSA-N NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)[C@@H](C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)CN(C)C)=O Chemical compound NC1=C2C(=NC=N1)N(N=C2C=1C=NC=C(C=1)O)[C@@H](C)C=1OC(C2=CC=CC=C2C=1C1=CC(=CC=C1)CN(C)C)=O NFGBLTRSLXBEKH-KRWDZBQOSA-N 0.000 claims 1
- CSYRIQJYPUNICN-BDQAORGHSA-N S(=O)(=O)(O)C1=CC=C(C)C=C1.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O Chemical compound S(=O)(=O)(O)C1=CC=C(C)C=C1.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O CSYRIQJYPUNICN-BDQAORGHSA-N 0.000 claims 1
- XOLJSNIALCLSBQ-LMOVPXPDSA-N S(C)(=O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN(C)C)=O Chemical compound S(C)(=O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN(C)C)=O XOLJSNIALCLSBQ-LMOVPXPDSA-N 0.000 claims 1
- LQGGAIPDMFIUMU-BDQAORGHSA-N S(C)(=O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O Chemical compound S(C)(=O)(=O)O.NC1=C2C(=NC=N1)N(N=C2C=2C=NC=C(C2)O)[C@@H](C)C=2OC(C1=CC=CC=C1C2C2=CC(=CC=C2)CN2CCN(CC2)C)=O LQGGAIPDMFIUMU-BDQAORGHSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000000181 anti-adherent effect Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 208000025426 neoplasm of thorax Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 201000003957 thoracic cancer Diseases 0.000 claims 1
- 229950000339 xinafoate Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19167245 | 2019-04-04 | ||
| EP20711985.0A EP3947384B1 (en) | 2019-04-04 | 2020-03-24 | Isochromene derivatives as phosphoinositide 3-kinases inhibitors |
| PCT/EP2020/058168 WO2020200918A1 (en) | 2019-04-04 | 2020-03-24 | Isochromene derivatives as phosphoinositide 3-kinases inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240130T1 true HRP20240130T1 (hr) | 2024-04-12 |
Family
ID=66092138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240130TT HRP20240130T1 (hr) | 2019-04-04 | 2020-03-24 | Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12527797B2 (enExample) |
| EP (1) | EP3947384B1 (enExample) |
| JP (1) | JP2022526973A (enExample) |
| KR (1) | KR20210149077A (enExample) |
| CN (1) | CN113874376A (enExample) |
| AR (1) | AR118588A1 (enExample) |
| AU (1) | AU2020252904A1 (enExample) |
| BR (1) | BR112021019589A2 (enExample) |
| CA (1) | CA3135309A1 (enExample) |
| DK (1) | DK3947384T3 (enExample) |
| ES (1) | ES2970530T3 (enExample) |
| FI (1) | FI3947384T3 (enExample) |
| HR (1) | HRP20240130T1 (enExample) |
| HU (1) | HUE065052T2 (enExample) |
| IL (1) | IL286937A (enExample) |
| MA (1) | MA55479A (enExample) |
| MX (1) | MX2021011979A (enExample) |
| MY (1) | MY206575A (enExample) |
| PH (1) | PH12021552402A1 (enExample) |
| PL (1) | PL3947384T3 (enExample) |
| PT (1) | PT3947384T (enExample) |
| SG (1) | SG11202110801XA (enExample) |
| SI (1) | SI3947384T1 (enExample) |
| TW (1) | TW202102504A (enExample) |
| WO (1) | WO2020200918A1 (enExample) |
| ZA (1) | ZA202107710B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024180207A1 (en) | 2023-03-02 | 2024-09-06 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| PT1158958E (pt) | 1999-03-05 | 2007-08-13 | Chiesi Farma Spa | ''composições farmacêuticas em pó, melhoradas, para inalação'' |
| LT2496567T (lt) | 2009-11-05 | 2017-11-27 | Rhizen Pharmaceuticals S.A. | Nauji benzopirano kinazės moduliatoriai |
| TWI672297B (zh) | 2013-12-18 | 2019-09-21 | 義大利商吉斯藥品公司 | 作為磷脂肌醇－３－激酶抑制劑之異唏衍生物 |
| ES2750791T3 (es) | 2014-06-17 | 2020-03-27 | Chiesi Farm Spa | Derivados de indolizina como inhibidores de fosfoinositido 3-quinasas |
| US9745308B2 (en) | 2014-09-12 | 2017-08-29 | Chiesi Farmaceutici S.P.A. | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors |
| US9968604B2 (en) | 2015-04-16 | 2018-05-15 | Chiesi Farmaceutici S.P.A. | Chromene derivatives as phoshoinositide 3-kinases inhibitors |
| WO2017134053A1 (en) | 2016-02-04 | 2017-08-10 | Chiesi Farmaceutici S.P.A. | Pyrazole derivatives as phosphoinositide 3-kinases inhibitors |
-
2020
- 2020-03-24 EP EP20711985.0A patent/EP3947384B1/en active Active
- 2020-03-24 MA MA055479A patent/MA55479A/fr unknown
- 2020-03-24 US US17/600,676 patent/US12527797B2/en active Active
- 2020-03-24 FI FIEP20711985.0T patent/FI3947384T3/fi active
- 2020-03-24 MX MX2021011979A patent/MX2021011979A/es unknown
- 2020-03-24 DK DK20711985.0T patent/DK3947384T3/da active
- 2020-03-24 HR HRP20240130TT patent/HRP20240130T1/hr unknown
- 2020-03-24 MY MYPI2021005864A patent/MY206575A/en unknown
- 2020-03-24 HU HUE20711985A patent/HUE065052T2/hu unknown
- 2020-03-24 CA CA3135309A patent/CA3135309A1/en active Pending
- 2020-03-24 WO PCT/EP2020/058168 patent/WO2020200918A1/en not_active Ceased
- 2020-03-24 PT PT207119850T patent/PT3947384T/pt unknown
- 2020-03-24 JP JP2021558911A patent/JP2022526973A/ja active Pending
- 2020-03-24 ES ES20711985T patent/ES2970530T3/es active Active
- 2020-03-24 PH PH1/2021/552402A patent/PH12021552402A1/en unknown
- 2020-03-24 SI SI202030355T patent/SI3947384T1/sl unknown
- 2020-03-24 PL PL20711985.0T patent/PL3947384T3/pl unknown
- 2020-03-24 SG SG11202110801XA patent/SG11202110801XA/en unknown
- 2020-03-24 KR KR1020217033595A patent/KR20210149077A/ko not_active Withdrawn
- 2020-03-24 BR BR112021019589A patent/BR112021019589A2/pt not_active Application Discontinuation
- 2020-03-24 AU AU2020252904A patent/AU2020252904A1/en not_active Abandoned
- 2020-03-24 CN CN202080034539.2A patent/CN113874376A/zh active Pending
- 2020-03-27 TW TW109110464A patent/TW202102504A/zh unknown
- 2020-04-03 AR ARP200100946A patent/AR118588A1/es not_active Application Discontinuation
-
2021
- 2021-10-03 IL IL286937A patent/IL286937A/en unknown
- 2021-10-12 ZA ZA2021/07710A patent/ZA202107710B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2970530T3 (es) | 2024-05-29 |
| CA3135309A1 (en) | 2020-10-08 |
| MX2021011979A (es) | 2021-11-03 |
| AU2020252904A1 (en) | 2021-11-18 |
| SG11202110801XA (en) | 2021-10-28 |
| AR118588A1 (es) | 2021-10-20 |
| ZA202107710B (en) | 2025-03-26 |
| JP2022526973A (ja) | 2022-05-27 |
| HUE065052T2 (hu) | 2024-04-28 |
| PH12021552402A1 (en) | 2022-06-20 |
| DK3947384T3 (da) | 2024-01-08 |
| EP3947384A1 (en) | 2022-02-09 |
| MY206575A (en) | 2024-12-24 |
| CN113874376A (zh) | 2021-12-31 |
| EP3947384B1 (en) | 2023-11-01 |
| WO2020200918A1 (en) | 2020-10-08 |
| FI3947384T3 (fi) | 2024-01-30 |
| US20220175784A1 (en) | 2022-06-09 |
| US12527797B2 (en) | 2026-01-20 |
| BR112021019589A2 (pt) | 2021-12-07 |
| MA55479A (fr) | 2022-02-09 |
| PT3947384T (pt) | 2024-01-29 |
| IL286937A (en) | 2021-10-31 |
| SI3947384T1 (sl) | 2024-03-29 |
| KR20210149077A (ko) | 2021-12-08 |
| PL3947384T3 (pl) | 2024-03-25 |
| TW202102504A (zh) | 2021-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026009899A (ja) | ＮａＶ１．８を阻害するピリジンカルボキサミド化合物 | |
| AU2014225761B2 (en) | Compounds for treatment of cancer | |
| HRP20180212T1 (hr) | Derivati 1-fenil-2-piridinilalkil-alkohola kao inhibitori fosfodiesteraze | |
| JP2014037426A5 (enExample) | ||
| HRP20201435T1 (hr) | Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora | |
| RU2009127095A (ru) | Новые оксадиазольные соединения | |
| JP2017504635A5 (enExample) | ||
| RU2012153164A (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути | |
| HRP20100670T1 (hr) | Aril-supstituirani pirazol-amid spojevi korisni kao inhibitori kinaze | |
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| RU2015121046A (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| JP2020509022A5 (enExample) | ||
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| JP2013510825A5 (enExample) | ||
| HRP20100020T1 (hr) | Novi derivati hidantoina za liječenje opstruktivnih bolesti dišnih putova | |
| JP2018525430A5 (enExample) | ||
| US9828370B2 (en) | Compositions and methods for inhibiting kinases | |
| RU2015121037A (ru) | Производные фенилэтилпиридина в качестве ингибиторов pde-4 | |
| MX2012002534A (es) | Derivados de (tio) morfolina como moduladores de esfingosin-1-fosfato. | |
| TW200604198A (en) | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | |
| CA2541781A1 (en) | 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of respiratory illnesses | |
| HRP20202025T1 (hr) | Kondenzirani derivati tiofena korisni kao inhibitori napi-iib |